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vascular smooth muscle cells 
Daryoush Ekhterae, PhD, and James C. Stanley, MD,  Ann Arbor, Mich. 
Purpose: Enhancement of the fibrinolytic activity of vascular cells by tissue plasminogen 
activator (t_PA) gene transfer has considerable clinical potential. However, it is unknown 
whether greater constitutive xpression of the tPA gene might increase plasminogen 
activator inhibitor-1 (PAI-1) secretion, which could negate expected increases in 
fibrinolytic activity that accompany greater tPA protein production. The objective of this 
investigation was to determine whether transduction ofhuman endothelial cells (EC) and 
vascular smooth muscle cells (SMC) with a retroviral vector containing the human tPA 
gene would increase tPA production and what effect his would have on endogenous 
PAI-1 secretion and subsequent fibrinolytic activity. 
Methods: Cultivated human EC and SMC either were transduced with a murine leukemia 
retroviral vector (MFG) containing the human tPA gene and, in the case of controls, the 
lacZ gene, or they were exposed to media alone. On days 14 and 28 after transduction, 
supernatent tPA antigen and PAI-1 antigen levels were measured by ELISA, and 
supernatent tPA activity was quantitated with a spectrolyse tPA/PAI assay. 
Results: Southern and Northern blot analyses documented integration and transcription 
of the tPA gene in both EC and SMC. Greater tPA antigen production occurred in 
MFG-tPA-transduced EC and SMC compared with nontransduced or MFG-lac Z-trans- 
duced cells (p < 0.05). The tPA activity increased in transduced human saphenous vein 
EC (up to 5.1-fold) and human iliac artery EC (up to 4.7-fold), but no increased tPA 
activity occurred in transduced SMC, compared with nontransduced or MFG-lac 
Z-transduced cells (p < 0.05). PAI-1 antigen was unchanged in transduced SMC but 
decreased in MFG-tPA-transduced EC (p < 0.05). PAI-1 mKNA was unchanged in the 
transduced EC and SMC compared with nontransduced cells, suggesting that posttrans- 
lational events may have caused the changes in EC PAI-1. 
Conclusions: This investigation demonstrated that MFG-mediated tPA gene transfer into 
human EC resulted in a significant increase in tPA activity. Enhancement ofadult human 
EC fibrinolytic activity by transfer of the human tPA gene has not been previously reported 
and represents a necessary finding in the development ofthis gene therapy technology for 
the prevention of thrombotic complications of vascular disease. (J VAsc SURG 
1995;21:953-62.) 
Endothelial cells (EC), because of their immedi- 
ate interface with blood, are an attractive target for 
genetic transfer to enhance secretion of antithrom- 
botic and thrombolytic proteins.l-4 Vascular smooth 
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muscle cells (SMC) are in close proximity to the 
bloodstream in certain clinical settings, such as after 
endarterectomy or balloon angioplasty, and are also 
a relevant target cell for gene transfer directed toward 
prevention of  arterial thrombosis. In addition, SMC 
exist in multilayers in the vessel wall and thus provide 
a substantial increase in target cell numbers, a factor 
that may be important where large quantities of 
transduced cells are needed for therapy, s 
The endothelium plays a critical role in the 
regulation of intravascular coagulation and fibrino- 
lysis. Fibrinolysis is regulated in part by a balance in 
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Table I. Increased tPA antigen and tPA activity after MFG-tPA gene transduction of 
human saphenous vein EC* 
Donor 1 Donor 2 Donor 3 
% % % 
Increase Increase Increase 
tPA Active in active tPA Active in active tPA Active in active 
antigen tPA tPA antigen tPA tPA antigen tPA tPA 
Day 14 of  culture 
A Nontrans- 10.5 +_ 1.2 2.2 -+ 0.0 
duced EC 
Transduced EC 48.6 -+ 1.9:) 5.4 -+ 1.0:) 
B Nontrans- 25.5 _+ 2.6 2.6 _+ 0.0 
duced EC 
Transduced EC 49.3 -+ 3.45 3.6 -+ 0.5 
Day 28 of  culture 
A Nontrans- 6.0 + 3.0 3.3 -+ 0.4 
duced EC 
Transduced EC 59.5 -+ 11.2:) 6.6 -+ 1.4 
B Nontrans- 27.9 + 3.9 2.7 _+ 0.5 
duced EC 
Transduced EC 53.5 -+ 5.15 4.1 _+ 0.45 
6.8-+ 0.6 3 .1 -0 .2  Ot 1.0_+0.1 
145 61 510 
34.6 + 0.1~: 5.0 + 1.6 28.1 -+ 1.5:) 6.1 _+ 0.44 
14.9 -+ 1.4 2.8 +- 0.2 O-j- 0.9 _+ 0.6 
24 79 111 
52.5 -+ 8.3k 5.0 -+ 0.1~: 13.3 + 1.5:) 1.9 + 0.15 
79 
13.0 _+ 0.0 2.8 + 0.3 21.8 -+ 1.1 1.7 + 0.0 
100 50 324 
34.5 -+ 7.6:) 4.2 + 1.2 142.3 _+ 28.0:)[: 7.2 + 1.3:) 
7.8 -- 3.4 2.0 + 0.1 20.6 + 1.8 2.1 _+ 0.7 
52 165 71 
86.4 -+ 4.2:) 5.3 + 0.0:) 47.7 + 7.2:) 3.6 + 1.0 
A, Media or MFG-tPA vector exposure of  EC 3 days after plating; B, media or MFG-tPA vector exposure of  EC 5 days after plating. 
*The tPA antigen and activity in ng/ml/106 cell/hr, expressed as mean of triplicate culture plates -+ 1 SD. 
1-Level below detectable assay r nge. 
Sp < 0.05, statistical comparison of  transduced to nontransduced EC. 
the secretion of tissue plasminogen activator (tPA) 
and plasminogen activator inhibitor-1 (PAl-l) by 
endothelial cells (EC). 6"9 In this regard, it may be 
possible to reduce the luminal thrombogenicity of 
diseased arteries and veins, as well as synthetic grafts, 
by altering the production of tPA and PAl-1 in favor 
of tPA. 
Many investigators have explored tPA gene trans- 
fer as a method to increase tPA activity, thereby 
reducing vascular thrombogenicity. We and others 
have previously documented successful transduction 
of nonhuman EC with replication incompetent 
retroviruses containing the tPA gene. 2,3a°'n Dichek 
et al. a have shown that transfer of the human tPA 
gene to sheep EC resulted in increased tPA secretion. 
However, a significant portion of the recombinant 
human tI'A secreted was bound to sheep PAI-1, thus 
diminishing the net increase in actual fibrinolytic 
activity. The effect of transfer of the human tPA gene 
into adult human EC on tPA and PAl-1 production 
has not been studied. This is considered essential 
before pursuing the application of this technology to
human gene therapy. 
In this investigation, the use of retroviral- 
mediated transfer of the human tPA gene into human 
EC and SMC as a means of enhancing their 
fibrinolytic activity was assessed. These studies dem- 
onstrated that tPA-transduced EC had significantly 
greater fibrinolytic activity than did nontransduced 
control EC. Decreases in EC PAI-1 may have 
contributed to this increase in activity. Transduction 
of SMC resulted in increased secretion of tPA 
antigen, but in contrast to EC, its fibrinolytic activity 
was not significantly enhanced. Furthermore, SMC 
PAl-1 was not significantly affected by tPA gene 
transfer, and it is likely that the relatively low 
increases in tPA were insufficient to overcome the 
existing PAl-1 activity. 
METHODS 
EC and SMC harvest and culture. EC and 
SMC were procured from human saphenous vein 
segments obtained from patients undergoing coro- 
nary artery bypass, and iliac artery segments were 
obtained from liver transplant donors. This was 
undertaken with approval from the Institutional 
Review Board of the University of Michigan Hos- 
pitals. The saphenous veins were placed in heparin- 
ized blood, and iliac artery segments were placed in 
University of Wisconsin solution for transport to the 
laboratory for cell harvest. Neither transport medium 
is believed to have a specific protective ffect on EC 
or SMC tPA production, although rigorous tudies 
to confirm such have not been performed. 
EC were derived with standard enzymatic tech- 
niques. ~2 The lumina of the explanted vessels were 
flushed with 10 ml of Dulbecco's phosphate buffered 
saline solution. The vessels were filled with 5 ml of 
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Table II. Increased tPA antigen and tPA activity after MFG-tPA gene transduction of 
human iliac artery EC* 
Donor 4 Donor 5 
% Increase % Increase 
tPA Active in active tPA Active in active 
antigen tPA tPA antigen tPA tPA 
Day 14 of  culture 
A Nontrans- 0t  0.9 -+ 0.2 2.4 +- 2.0 5.6 -+ 1.2 
duced EC 467 61 
Transduced EC 26.0 - 0.5~ 5.1 _+ 0.3~ 70.0 -+ 1.15 9.0 -+ 1.5 
B Nontrans- 0t  1.8 _+ 0.6 1.9 -+ 0.0 4.3 +- 0.6 
duced EC 28 93 
Transduced EC 16.4 -+ 0.25 2.3 -+ 0.2 68.0 -+ 7.7~ 8.3 -+ 3.2 
C Nontrans- 0t  0.5 -+ 0.2 1.5 -+ 0.2 ND 
duced EC 420 ND 
Transduced EC 5.3 -+ 0.35 2.6 -+ 1.1 74.0 -+ 7.75 ND 
Day 28 of  culture 
A Nontrans- 0t  2.9 -+ 0.1 0t  ND 
duced EC 121 ND 
Transduced EC 66 +_ 23~ 6.4 _+ 2.1 112.2 _+ 26.2~ ND 
B Nontrans- 0~ 0.9 0t  5.5 +- 0.0 
duced EC 233 271 
Transduced EC 21.2 -+ 4.85 3.0 _+ 0.8 86.6 -+ 13.0# 20.4 _+ 9.7 
C Nontrans- 0t  1.3 -+ 0.3 0.4 +_ 0.0 13.3 -+ 0.0 
duced EC 85 53 
Transduced 8.0 +_ 0.6~ 2.4 +- 0.7 85.4 -+ 25.25 20.3 -+ 3.0t 
A, Media or MFG-tPA vector exposure of EC 3 days after plating; B, Media or MFG-tPA vector exposure of  EC 4 days after plating; 
(2, Media or MFG-tPA vector exposure of  EC 5 days after plating. 
*The tPA antigen and activity in ng/ml/106, expressed as mean of triplicate culture plates -+ 1 SD. 
tLevel below detectable assay range. 
Sp < 0.05, statistical comparison of  transduced to nontransduced EC. 
dispase (Boehringer Mannheim, Indianapolis, Ind., 
40 U/ml) and incubated for 20 minutes at 20 ° C. 
After incubation, the vessels were flushed with 20 ml 
of M199, and the ffluent was centrifuged at 1200 
rpm for 10 minutes. The resulting EC pellets were 
resuspended in 5 ml of M199 containing 50 U/ml 
penicillin, 50 mg/ml streptomycin, 25 Ixg/ml endo- 
thelial cell growth supplement, 15 U/ml heparin, 2 
mmol/L glutamine, and 20% bovine plasma-derived 
serum. These EC were then plated on to gelatin- 
coated T25 flasks for subsequent culture, with the 
media being changed on alternate days. Confluent 
cells were split 1:8. Demonstration of the ligand 
Dil-AC low-density lipoprotein by fluorescent mi- 
croscopy and morphologic assessment by light mi- 
croscopy confirmed that more than 99% of the 
cultivated cells were EC. 
SMC were derived from human ifiac arteries 
with a modification of a standard enzymatic tech- 
nique. 13 SMC were derived after intimal and adven- 
titial layers were mechanically removed from the 
artery by scraping with a scalpel blade. The remaining 
medial layer was cut into 1 to 3 mm 2 sections. These 
tissues were placed in 10 ml of a collagenase and 
elastase solution (collagenase at 1.8 mg/ml and 
elastase at 0.2 mg/ml) and agitated for i to 1.5 hours 
at 37 °C. Single-ceU suspensions were then removed 
and pelleted by centrifugation at 1200 rpm for 10 
minutes. These SMC were resuspended in M199, 
containing 20% bovine calf serum, 2 mmol/L 
glutamine, 50 U/ml penicillin, and 50 ~tg/ml strep- 
tomycin. The SMC were plated on gelatin-coated 
T25 flasks for culture. The SMC were split at 
confluence. This cultivation technique resulted in a 
cell population of greater than 99% SMC as deter- 
mined by a-actin immunofluorescent staining. 
Gene transfer. The MFG-tPA vector, a Moloney 
murine leukemia virus-based vector with certain cod- 
ing sequences removed, and the cDNA for human 
tPA inserted into it were used in this investigation 
and have been described earlier (Fig. 1). 14 The MFG- 
tPA vector provided by L. Cohen (Somatix, Ala- 
meda, Calif.) The expression of tPA gene was driven 
by the LTR promoter. The virus-containing medium 
(VCM) had a titer of 5 × l0 s to 1.5 × 106 CFU/ml 
and was negative for the presence of helper virus? 4 
Similarly, in the MFG-lacZ vector, the expression of 
the lacZ gene was driven by the LTR promoter. The 
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Fig. 1. MFG tPA is retroviral-based vector containing human tPA cDNA. This vector consists 
ofMoloney murine leukemia virus LTRs and human tI'A cDNA. Important restriction sites are 
Kpn I, Cla I, Nhe I. SD, splice donor sequence; ~ retroviral packaging sequence; I@, kilobases; 
bp, base pair. Fragment Cla I to NheI was excised, labeled, and used as probe for Southern and 
Northern analyses. 
MFG-lacZVCMhadat i terof l  x 10Stol.5 x 106 
CFU/ml and was negative for the presence of helper 
virus.  
EC at passage 3 were plated on T25 flasks at a 
density of 5000 cells/cm 2.At 3 to 5 days after plating 
(log phase growth), the EC were exposed to 5 ml of 
VCM containing 8 ~g/ml of polybrene and incu- 
bated for 12 hours. SMC at passage 2 were similarly 
plated on T25 flasks at a density of 5000 cells/cm 2.At 
3 days after plating, the SMC were washed and 
exposed for either 30 minutes or 14 hours to VCM 
containing 8 ~g/ml ofpolybrene. After the exposures 
the VCM was removed, the EC and SMC were 
washed with Dulbecco's phosphate buffered saline 
solution, and the growth media was replaced. These 
cells were then maintained in culture. The condi- 
tioned medium was collected at day 14 and 28 of 
culture and assayed for tPA and PAI-1 as described 
below. RNA and DNA were extracted for analysis 
from a subset of remaining cells of the 14- and 28-day 
cultures. 
Quantitation of  human tPA antigen and 
PAI-1 antigen. Secreted tPA was assayed by 
measuring t_PA antigen in the supernatant medium at 
days 14 and 28 of culture. Medium for assay was 
collected 12 hours after addition of 5 ml fresh 
enriched M199. The tPA antigen was quantified 
with an ELISA-enzyme-linked immunosorbent as- 
say (Immunobind-5; American Diagnostica, Inc., 
Greenwich, Conn.) is and was expressed as ng/ml/106 
cells/hr. Human PAI-1 antigen secretion in the 
supernatant medium was similarly measured with an 
ELISA (Immunobind-PAI-1; American Diagnos- 
tica, Inc.) 16 and was also expressed as ng/ml/106 
cells/hr. This method measures combined free and 
bound tPA. The antibody used has less affinity for 
bound PAI-1 than free PAI-1, although exact affinity 
levels have not been established. The lower limit of 
detection of the assays was approximately 0.2 ng/ml. 
The reproducibility of these ELISA assays was 
greater than 97%. 
Quantitation of human tPA activity. The tPA 
activity was measured at days 14 and 28 of culture. 
Subsequent to the initial media collection for tPA 
antigen assay, the cells were washed twice and incu- 
bated in 5 ml serum-free M199 with added 
glutamine. The culture supematant was collected af- 
ter 6 hours of incubation and acidified immediately 
with an equal volume of sodium acetate buffer 
(1 tool/L, pH 3.9) to prevent further reaction be- 
tween free human tPA and any endogenous human 
PAl. 17 This medium was frozen immediately at 
-70  ° C for later assay. Each sample had the tPA 
activity measured with a spectrolyse tPA/PAI kit 
(American Diagnostica, Inc.) 18 This assay does not 
measure fibrin or other protein degradation prod- 
ucts. The tPA activity was defined in international 
units/milliliter, then converted to tPA antigen section 
rates as ng/ml/106 cells/hr with an ELISA of the tPA 
activity standards. These values were then divided by 
actual antigen secretion rates to obtain the percent 
active tPA. Samples with tPA in the range of 0.003 to 
0.03 IU/ml can be assayed by this method. This assay 
is tenfold to 100-fold more sensitive than the antigen 
assay. The reproducibility of the activity assay was 
greater than 97%. 
Southern blot analysis. DNA was extracted 
from EC after 14 and 28 days of culture, and analyzed 
for proviral DNA. t9 DNA was digested with KpnI 
and subjected to electrophoresis ona 1% agarose gel. 
JOURNAL OF VASCULAR SURGERY 
Volume 21, Number 6 Ekhterae and Stanley 957 
< 
C E 1E  2 E 3 E 4 C E 5 E 6 E 7 E 8 
Fig. 2. Representative Southern blot analysis of human EC transduced with MFG-tPA vector. 
Genomic DNA, 10 txg, from nontransduced (C) and transduced cells (E) were electrophoresed 
on 1% agarose. Kpn I digest 17.5 pg of plasmid representing o ecopy per cell was also 
electrophoresed into same gel. Blot was hybridized to 32p labeled "LTR" probe, which 
represents 172 bp of retroviral vector; Cla I to Nhe I fragment. Lanes in blot were quantitated 
by use of Betascope 630 blot analyzer. C, nontransduced control; EC lanes E1 to E4, human 
iliac artery EC. Lane E1andE2, EC transduced 3 and 4 days after plating (harvested at day 14); 
lane E3 and E4, EC transduced 3 and 4 days after plating (harvested at day 28). Lane 5 and 6, 
saphenous vein EC transduced 3 and 5 ays after plating (harvested at day 14). Lane E7 and 
E8, saphenous vein EC transduced 3 and 5 days after plating (harvested at day 28). 
Subsequently, 10 Ixg genomic DNA from each 
sample were transferred to a zeta probe membrane 
(Biorad Inc., Richmond, Calif.). The blots were 
hybridized overnight at 42 ° C to a 172 bp ClaI-NheI 
fragment of MFG tPA vector (Fig. 2), which was 
radiolabeled with phosphorous 32 deoxycytidine 
triphosphate with a random primer method. 2° Mem- 
branes were washed in 0.2 saline citrate and 0.1% 
sodium dodecyl sulfate at 55 °C. Autoradiographs at 
-70  ° C were obtained with Kodak XAR film 
(Eastman Kodak Co., Rochester, N.Y.). The blots 
were stripped and hybridized with a ff'A cDNA, 21 
and subsequently they were exposed to phosphor 
screens for quantification on a Model 400 phospho- 
rimager (Molecular Dynamics, Sunnyvale, Calif.). 
The efficiency of gene transfer was determined by 
comparing the band intensity of arterial and venous 
EC blots to that of 17.5 pg of murine leukemia 
retroviral vector (MFG)-tPA plasmid DNA, repre- 
senting one gene copy per cell. The agarose gel, used 
for electrophoresis of DNA extracted from control 
and MFG-tPA-transduced EC, was stained with 
ethidium bromide to confirm tmiformity of DNA 
loading. 
Northern blot analysis. Total cellular RNA was 
extracted from EC and SMC by the method of 
Chromczynski and Sacci. 22 Seven micrograms (Fig. 
3) or 10 ~g (Fig. 4) of each sample was subjected to 
electrophoresis through 1.2% formaldehyde agarose 
gels. The RNA was then blotted onto nitrocellulose 
membranes (Schleicher and Schuell, Inc., Keene, 
N.H.) that were subsequently vacuum-dried. The 
Northern blot hybridization, washing, and autoradi- 
ography were performed as described for the South- 
ern blot analysis. The blots were hybridized to a 172 
bp fragment of MFG-tPA, human PAI-1 cDNA, 23 or 
human glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) cDNA and quantitated on a Betascope 
630 (Molecular Dynamics). The blots were stripped 
and rehybridized to a tPA cDNA and subsequently 
exposed to phosphor screens for quantification on a 
Model 400 phosphorimager (Molecular Dynamics). 
Statistical analysis. The tPA and PAI-1 data are 
reported as mean _+ 1 SD. Statistical comparisons 
between transduced and nontransduced EC and 
SMC were undertaken with use of the Student  test. 
RESULTS 
Quantitation of human tPA antigen and 
PAI-1 antigen. Retroviral mediated transfer of the 
human tPA gene into human arterial and venous EC 
resulted in substantial increases in their fibrinolytic 
activity. Significantly higher increases (p = 0.005 to 
0.001) in tPA antigen and activity were detected in 
the culture supernatant of transduced EC compared 
with nontransduced control EC at both 14 and 28 
days of culture (Tables I, II, and III). Although 
tPA-transduced vascular SMC exhibited significantly 
higher levels (p < 0.05) of tPA antigen compared 
with nontransduced SMC controls, there was no 
significant increase in the tPA activity of transduced 
SMC (Table IV). A significant decrease in endog- 
enous PAI-1 antigen was detected in transduced EC, 
yet no significant change of PAI-1 antigen was 
detected in similar transduced SMC. It is possible 
that the relatively low levels of tPA antigen produced 
by the SMC were not sufficient o overcome the 
moderate l vels of PAI-1 produced by the same cells. 
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Fig. 3. Representative Northern blot analysis of human iliac and saphenous EC transduced 
with MFG-tPA. Total cellular RNA was extracted, 7 ~tg were fractionated on 1.2% 
formaldehyde agarose gels, blotted and hybridized to a 32P-labelled "LTR" probe (A), PAI-1 
probe (B), or GAPDH probe (C). Lane C1, human iliac artery EC, control, harvested at day 
14. Lane C2, human saphenous vein EC, control, harvested at d y14. Lanes El, E3, E5, E7, 
E8, iliac artery EC, transduced at 3, 4, and 5 days after plating, harvested at day 14 or transduced 
at 4 and 5 days after plating, harvested at day 28, respectively. Lanes E2, E4, E6, represent 
saphenous vein EC, transduced at 3 and 5 days after plating and harvested at day 14 or 
transduced at 5 days after plating and harvested at day 28, respectively. Intensity of band for tPA 
was normalized to GAPDH: El, 2.5; E3, 1.4; E5, 0.32; E2, 2.4; E4, 2.1. Average intensity of 
two bands for PAI was normalized to GAPDH: C1 = 0.125, E1 = 0.125; C2 = 0.18, 
E2 = 0.17. 
C1 E1 02 E203 E3C4 E4 
r t -PA-  A 
h-PAI I 3.2 Kb- 
2.2 Kb- 
B 
GAPDH- C 
Fig. 4. Representative Northern blot analysis of human iliac artery SMC transduced with 
MFG-tPA. Total cellular RNA 10 ixg was electrophoresed and probed with "LTR" probe (A) 
or PAI-1 (B), or GAPDH probe (C). Lanes C1, C2, C3, and C4 represent nontransduced 
control for 30 minutes or 14 hours, harvested at day 14 and day 28, respectively. Lanes El, E2, 
E3, andE4 represent transduced for either 30 minutes, or 14 hours, harvested at day 14 and day 
28, respectively. Intensity of band for tPA was normalized to GAPDH:E1, 0.22; E2, 1.1; E3, 
0.29; E4, 2.3. Average intensity of two bands for PAI was normalized to GAPDH: C1 = 0.07, 
E1 = 0.07; C2 -- 0.07, E2 = 0.07; C3 = 0.07, E3 = 0.08; C4 = 0.13, E4 = 0.15. 
Southern  b lot  analysis. Depending on the 
manner of  transduction and t iming of  analysis, the 
tPA transduced iliac artery EC had 0.2, 0.11, 0.24, 
and 0.54 gene copies per cell (Fig. 2; Table II,  donor  
5). Similarly, the tPA transduced saphenous EC had 
1.1, 0.41, 0.59, and 0.39 gene copies per cell (Fig. 2, 
Table I, donor 3). The band for the endogenous tPA 
in these blots represented one copy per cell (demon- 
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Table III. Relation of tPA antigen and PAl- 1 antigen production after MFG-tPA gene 
transduction of human saphenous vein and iliac artery EC* 
Saphenous Vein EC ~iacA~e~EC 
Donor 6 Donor 7 Donor 8 Donor 9 Donor 10 Donor 11 
tPA antigen tPA antigen tPA antigen tPA antigen tPA antigen tPA antigen 
(PAl-1 antigen) (PAl-1 antigen) (PAI-1 antigen) (PAL1 antigen) (PAI-1 antigen) (PAl-1 antigen) 
Nontransduced EC 35 -+ 21 2 .+ 1 4 + 2 1 -+ 1 1 -- 0 2 .+ 1 
(185 .+ 28) (209 -+ 23) (706 + 127) (465 .+ 146) (3491 .+ 1377) (1758 + 791) 
Transduced EC~- 57 -+ 29 26 _+ 35 31 .+ 3:~ 13 -+ 05 33 -+ 85 16 +_ 35 
(114 .+ 14)~ (172 -+ 93) (355 .+ 48):~ (195 .+ 19)~ (485 .+ 16)$ (146 .+ 26)$ 
~The tPA antigen and activity in ng/ml/106, expressed as mean of triplicate culture plates .+ 1 SD. 
tMedia or MFG-tPA vector exposure of  EC 3 days after plating; assays performed ay 14 of  culture. 
:~p < 0.05, statistical comparison of  transduced to nontransduced EC. 
Table IV. Relation of ff'A antigen/activity and PAI-1 antigen production 11 and 25 days after 
MFG-tPA transduction of human iliac artery SMC ~ 
Donor 12 Donor 13 
tPA Active (Increase in PALl tPA Active (Increase in PAI-I 
Antigen tPA Active tPA) Antigen Antigen tPA Active tPA) Antigen 
Day 14 of  culture 
A Nontrans- 1.3 _+ 0.2 0.5 -+ 0.0 234.4 _+ 6.9 ND 1.5 -+ 0.1 
duced SMC (0%) (0%) 
Transduced 2.6 _+ 0.2t 0.5 _+ 0.0 212.9 _+ 8.7 ND 1.3 -+ 0.0 
SMC 
B Nontrans- 0~z 0.5 -- 0.1 231.3 -+ 15.6 6.2 -+ 2.9 2.9 _+ 0.4 
duced SMC (0%) (0%) 
Transduced 12.1 -+ OAt 0.5 _+ 0.0 204.3 -4- 14.5 31.4 _+ 4.3t  2.4 .+ 0.3 
SMC 
Day 28 of  culture 
ANontrans-  1.1 + 0.1 0.5 259.5 -+ 31.7 15.7 .+ 0.3 3 
duced SMC (20%) (27%) 
Transduced 3.9 -+ 0.41- 0.6 .+ 0.1 299.0 _+ 1.6 15.9 -+ 0.2 4.1 .+ 0.8 
SMC 
B Nontrans- 05 0.5 .+ 0.0 253.7 .+ 18.4 22.4 .+ 1.2 ND 
duced SMC (0%) ND 
Transduced 17.5 .+ 2.47 0.5 -+ 0.0 230.2 .+ 18.4 32.6 -+ 3.2t ND 
SMC 
818.7 _+ 71.0 
733.8 _+ 17.3 
1298.1 + 233.6 
1225.1 _+ 129.1 
844.0 _+ 26.7 
1336.6 -+ 259.8 
2106.7 _+ 330.5 
1731.9 -+ 101.7 
A,  Media or MFG-tPA vector exposure for 30 minutes; B, Media or MFG-tPA vector exposure for 14 hours; ND, not determined. 
~The tPA antigen and activity in ng/ml/106, expressed as mean of triplicate culture plates -- 1 SD. 
tp < 0.05, statistical comparison of transduced to nontransduced EC. 
SLevel below detectable assay r nge. 
strating that equal amounts of sample were loaded 
onto each lane). The efficiency of the transduction 
was estimated to be twice as great when cells were 
transduced at 3 days after plating than at 4 or 5 days 
after plating (0.20 vs 0.11 or 1.1 vs. 0.41 gene copies 
per cell). The level of tPA production corresponded 
with the number of gene copies per saphenous EC 
but not he number ofgene copies per iliac artery EC. 
Northern blot analysis (EC). Northern blot 
analysis of transduccd EC confirmed the presence of 
appropriate tPA mRNA (Fig. 3, saphenous vein EC
donor 1, and iliac artery EC donor 1). The levels of 
this mRNA were normalized to human GAPDH 
mRNA. In this manner the relative amounts of 
mRNA were determined by dividing the number of 
counts per minutes of each sample by counts per 
minute of GAPDH of the same sample. The ratios 
calculated by this method revealed that the quantities 
of exogenous mRNA in the Northern blots from lilac 
artery and saphenous vein EC corresponded with 
observed tPA antigen production. 
Northern blot analysis (SMC). Northern blot 
analysis of transduced SMC also revealed a high level 
of exogenous gene mRNA (Fig. 4, donor 12). These 
mRNA levels were also normalized to GAPDH. The 
levels of transduced cells' tPA mRNA corresponded 
with the amounts oftPA antigen produced. The ratio 
of exogenous to endogenous tPA transcript (El: 1.2, 
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E2 : 4, E3 : 1.2, E4 : 3) correlated with the amounts of 
tPA antigen produced (Table IV). Although signif- 
icant tPA gene transfer and expression occurred in 
SMC, this did not correspond with enhanced tPA 
activity (Table IV). 
The introduction of a new tPA gene into EC and 
SMC appeared to result in significant decreases in
PAL1 antigen levels in EC (Table III), but such did 
not occur in SMC (Table IV). Northern blots, 
hybridized with the PAI-1 cDNA, 24 revealed no 
significant change in PAI-1 mRNA in EC or SMC 
after the t_PA gene transfer (Figs. 3 and 4). The 
average intensity of the two bands for PAI were 
normalized to GAPDH. These data suggest that the 
decreases in PALl antigen, when present, may have 
been due to translational orposttranslational events. 
DISCUSSION 
These studies demonstrate for the first time that 
retroviral-mediated gene transfer can be used to 
enhance the fibrinolytic activity of adult human EC. 
Retroviral-mediated gene transfer had been shown 
previously by others to enhance fibrinolytic activity of 
sheep EC and canine EC. 3'4 Sheep arterial and venous 
EC transduced with a retroviral vector containing the 
tPA gene and a selectable neomycin resistance gene 
expressed tPA at a rate of 10 to 28 ng/ml/106 
cells/hr? The tPA gene expression i  canine jugular 
vein EC with one 12-hour etroviral exposure to the 
MFG-tPA vector was 28 ng/ml/lO 6cells/hr, and two 
12-hour exposures increased the level of tPA expres- 
sion to 53.1 ng/ml/106 cells/hr. 4
In this study, recombinant tPA expression by 
human EC ranged from approximately 5 ng/ml/106 
cells/hr (Table II, donor 4, condition C, day 14) to 
120 ng/ml/106 cells/hr (Table I, donor 3, condition 
A, day 28). Median expression was 62 ng/ml/106 
cells/hr. Control saphenous vein EC from one donor 
and iliac artery EC from another donor when exposed 
to complete media lone expressed tPA at a rate of 6.9 
and 0.2 ng/ml/106 cells/hr, respectively. When the 
cells from these same donors were transduced with 
MFG-lacZ, the cells expressed tPA at a rate ofl.5 and 
0.2 ng/ml/lO 6cells/hr, respectively. Thus tPA secre- 
tion as the result of MFG-t_PA transduction was not 
a nonspecific response to retroviral transduction 
alone. In our study t_PA expression by nontransduced 
saphenous vein EC was generally higher than that 
from iliac artery EC, and supports the observation 
that the site of vascular EC origin may affect tPA 
expression. 25 
Efficient retroviral-mediated g ne transfer can be 
achieved best when the cells are actively dividing.  26'27 
Gene transfer and expression was higher with VCM 
exposure in the cells exposed 3 days after plating than 
in cells exposed 4 or 5 days after plating (Tables I and 
II). The doubling time of EC in our in vitro system 
is 2 to 3 days. Thus the multiplicity of infection (i.e., 
number of viral particles/number of cells) is about 
half at day 5 as compared with day 3. This is likely to 
have contributed tothe difference in the efficiency of 
the transduction we observed between days 3 and 5. 
With regard to efficiency ofgene xpression, two 
issues are noteworthy. First, the efficiency of MFG- 
ff'A gene transfer and gene expression i canine EC 
may be different han that in human EC. Second, 
there is a greater range of efficiency of gene expres- 
sion with different primary human EC cultures 24'26 
compared with that with canine EC. Nevertheless, 
with MFG retroviral vector, with one transduction 
without selection, gene expression efficiencies of up 
to 60% have been reported, z4,28 
Northern blot analyses oftPA-transduced EC and 
SMC revealed stable and persistent levels of gene 
expression for the modest lengths of time studied in 
these experiments. The level of recombinant gene 
expression in transduced cells was relatively high 
from day 14 to day 28 of culture in our study. In this 
regard, the vector design and packaging line make a 
significant difference in the stability of gene expres- 
sion. 29 The MFG-tPA vector used in our studies does 
not contain aselectable marker, and the simplicity of 
this construct may contribute to itslongevity in later 
expression. Although the basis for long-term retro- 
viral vector-mediated transgene expression is poorly 
understood, genetic and epigenetic factors have been 
implicated in the loss or decline of gene expres- 
sion. 3°,3~ Further studies are r quired to determine 
whether transcriptional or mRNA stability have 
changed in this setringY 
The MFG retroviral vector has been specifically 
engineered to limit the possibility of helper virus 
production. ~4,2s This vector has been used to achieve 
a high transduction efficiency without selection. 28
Some investigators have reported an efficiency of 
transduction i  human primary tumor cell cultures of 
no better than one in 100 tumor cells with vectors 
carrying selectable genes. 2.'28 Long-term cultures 
often cannot be established for many human tumor 
explants, and thus vectors containing selectable genes 
may not be as useful to generate large numbers of 
genetically transduced cells? 3 Even when long-term 
cell lines have been established, posttransduction 
selection has been shown to have adverse cellular 
effects. 28 
In our experiments i  was increasingly difficult o 
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maintain human saphenous vein EC beyond passage 
5. Thus a high initial efficiency of gene transfer 
becomes crucial. Clearly, the efficient ransduction 
with the MFG vector eliminates the need for 
cotransduction with a selectable gene and subsequent 
cytotoxic drug selection of the cells in culture, both 
of which may adversely affect later cell function. 
The structure and size of tPA-transduced EC in 
our experiments appeared unaltered and normal. 
Jaklitsch et al.s4 have also reported that transduced 
EC expressing high levels of tPA have an unaltered 
phenotype. Increasing the duration of the rettoviral 
vector exposure resulted in significant increases in 
gene transfer and expression. However, adverse 
affects of long-term EC exposure to retroviral vectors 
are possible and were not rigorously studied in this 
investigation. 
Although transduced EC exhibited greater tPA 
activity, a significant portion of the secreted t_PA was 
inactive. This is most fikely due to binding of tPA by 
PAI-1. Dichek et al. s used casein plasminogen 
zymography to demonstrate that free human tPA 
could complex with sheep PAI. The assays for human 
tPA activity in these experiments determined the 
activity of free human tPA only) 8 
This technology may be advanced further by 
certain specific modifications. For example, mutants 
of human tPA that retain fibrinolytic activity but bind 
poorly to PAL1 are known, s5 If such tPA variants 
could be expressed in EC, they could be used as a 
means of directly enhancing the cells fibrinolytic 
activity. Recent studies have shown enhanced fibri- 
nolytic activity by anchoring single chain uroldnase 
plasminogen activator, atype of PA resistant to PAI, 
to the apical surface of EC. 36 
The potential to reduce the thrombogenicity of
native vessels or vascular prostheses by genetic 
alteration of their luminal linings has attracted 
considerable attention. Seeding of transduced EC on 
vessels whose intimal tissues have been removed, as 
well as on vascular prostheses placed in the arterial 
circulation, have proven feasible in the experimental 
setting, sT,ss The tPA may have an important role in 
the tube formation of human microvascular endo- 
thelial cells in vitro, s9 In this regard, seeding the 
microvascular bed with tPA-transduced EC may offer 
an approach to augment angiogenesis and collateral 
blood vessel formation in patients with severe, 
nonreconstructable arterial occlusive disease. 
Although arterial occlusive disorders are the most 
life threatening, venous thromboembolytic diseases 
are among the most disabling chronic vascular 
disorders. In this regard, it is known that elevated 
levels of PAI and low levels of tPA are common 
in patients with deep venous thrombosis. 4°,41 
Retroviral-mediated transfer of the tPA gene to EC 
seeded into venous beds at risk might result in 
significant regional enhancement of fibrinolytic ac- 
tivity and provide a means of reducing the progres- 
sion of venous thrombosis. 
Although it has been shown that it is possible to 
introduce genetically engineered EC into the vascular 
wall and express exogenous genes, there remain many 
issues to be addressed before this technology may be 
used in the treatment or prevention of vascular 
disease. It is not known whether the high level oftPA 
expression observed in our in vitro studies will occur 
in vivo, or what effects constitutive t_PA production 
will have on PAI production in vivo. Nevertheless, 
tPA-related gene therapy represents a novel and 
potentially important intervention for clinical throm- 
botic disorders. This study demonstrated that human 
EC can be genetically modified to increase tPA 
expression significantly and that this increase did not 
lead to an increase in PAI-1 expression. This result is 
important for in vivo application of tI?A gene 
transfer. IfPAI-1 expression had increased as a result 
of increased tPA expression, there might be no net 
effect of tPA expression on cellular fibrinolytic 
activity. Such was not the case in our in vitro studies 
with documented increases in ff'A activity occurring 
after human tPA gene transfer. 
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